Best GLP-1 Weight Loss Treatments of 2026

People who use GLP-1 medications often report changes such as:

Feeling fuller sooner
GLP-1s slow gastric emptying and enhance satiety signals, which may make it easier to eat smaller portions².

Fewer constant cravings
Clinical and real-world reports suggest reduced appetite and fewer food-related thoughts, particularly around high-sugar or late-night snacks².

More stable blood sugar
GLP-1 medications were originally developed for blood sugar management in type 2 diabetes, which may also support steadier energy levels for some people⁴.

Support for long-term consistency
GLP-1s are generally studied and prescribed as part of a longer-term approach focused on gradual, sustainable weight loss rather than rapid short-term changes²³.

GLP-1 medications:

• Require a prescription from a licensed clinician

• Are not suitable for everyone

• May cause side effects, especially early on

• Work best alongside basic lifestyle habits

That’s why choosing a provider with proper medical screening and follow-up support matters.

With so many companies now offering GLP-1 treatment online, it can be hard to know which ones are worth considering. The providers featured below were reviewed based on factors that matter most to patients, including:

• Medical qualification process

• Pricing transparency and affordability

• Consistency of reported results

• Safety standards and clinician oversight

• Insurance support (when available)

• Ongoing patient care and support

• Access to customer service

Each provider listed aims to help eligible adults move toward their weight loss goals responsibly.

¹ The GLP-1 effect? U.S. obesity rate falls for the first time in years

² GLP-1 Agonists: The Latest Obesity Long-Term Use Data

³ Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5–15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials

¹ Gallup polling data reported by ConsumerAffairs (2025) — The GLP-1 Effect? U.S. Obesity Rate Falls for the First Time in Years

² New England Journal of Medicine — STEP 1 Trial (Semaglutide 2.4 mg)

³ Systematic Review of Phase 3 Trials (2025) — Comparative efficacy and safety of semaglutide and tirzepatide (SURMOUNT-1 & STEP data)

⁴ FDA Drug Approval Summaries — GLP-1 receptor agonists for diabetes and chronic weight management

¹ Gallup polling data on U.S. obesity, as reported by ConsumerAffairs (2025)
https://www.consumeraffairs.com/news/the-glp-1-effect-us-obesity-rate-falls-for-the-first-time-in-years-110525.html

² New England Journal of Medicine — STEP 1 Trial: Semaglutide 2.4 mg
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

³ Head-to-head GLP-1 trial results comparing tirzepatide vs semaglutide (SURMOUNT-5), summarized by MedGateToday
https://medgatetoday.com/lillys-tirzepatide-superior-to-semaglutide-in-head-to-head-trial-showing-an-average-weight-loss-of-20-2-vs-13-7/

⁴ FDA Prescribing Information — Wegovy (semaglutide) for chronic weight management
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf